Mark my words the Vivitrol Division will be shrinking to basically nothing soon, why does the company need a slacker force when there has been minimal growth in 5 years, patent expiration is coming soon and the product can be a cash cow for the last couple years with minimal operational expenses and for some years to come especially since a generic competitor will be hard pressed to make a generic. We will see who is left when the blood bath commences, don’t hold out hope as your managers are all ready getting pressed on this!
